Chronic Inflammatory Demyelinating Polyradiculoneuropathy Clinical Trials

8 recruiting

Chronic Inflammatory Demyelinating Polyradiculoneuropathy Trials at a Glance

12 actively recruiting trials for chronic inflammatory demyelinating polyradiculoneuropathy are listed on ClinicalTrialsFinder across 6 cities in 27 countries. The largest study group is Phase 3 with 4 trials, with the heaviest enrollment activity in Berlin, St Louis, and New Haven. Lead sponsors running chronic inflammatory demyelinating polyradiculoneuropathy studies include Takeda, Tongji Hospital, and argenx.

Browse chronic inflammatory demyelinating polyradiculoneuropathy trials by phase

Treatments under study

About Chronic Inflammatory Demyelinating Polyradiculoneuropathy Clinical Trials

Looking for clinical trials for Chronic Inflammatory Demyelinating Polyradiculoneuropathy? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Chronic Inflammatory Demyelinating Polyradiculoneuropathy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Chronic Inflammatory Demyelinating Polyradiculoneuropathy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting

Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study

Chronic Inflammatory Demyelinating PolyradiculoneuropathyCIDPCIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
argenx200 enrolled23 locationsNCT07264426
Recruiting
Phase 2

A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Takeda36 enrolled20 locationsNCT06798012
Recruiting
Phase 3

A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
Grifols Therapeutics LLC40 enrolled2 locationsNCT07540221
Recruiting
Phase 3

A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work

Chronic Inflammatory Demyelinating PolyradiculoneuropathyPolyneuropathy, Inflammatory Demyelinating, Chronic
Sanofi140 enrolled124 locationsNCT06290128
Recruiting
Phase 3

A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

Chronic Inflammatory Demyelinating PolyneuropathyChronic Inflammatory Demyelinating PolyradiculoneuropathyCIDP
argenx160 enrolled19 locationsNCT07091630
Recruiting
Phase 3

A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Takeda59 enrolled52 locationsNCT06747351
Recruiting
Early Phase 1

Universal Chimeric Antigen Receptor T-Cell (UCAR T-cell) Therapy Targeting CD19/B Cell Maturation Antigen (CD19/BCMA) in Patients With r/r Neurological Autoimmune Diseases

Myasthenia GravisAutoimmune EncephalitisMultiple Sclerosis+2 more
Tianjin Huanhu Hospital12 enrolled1 locationNCT06939166
Recruiting

A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Takeda30 enrolled15 locationsNCT06538064
Recruiting

Our Study Aims to Determine if Nerve Alterations in Acute GBS and CIDP Detectable by Ultrasound Match Electrodiagnostic Findings and if This Method Aids Early Diagnosis, Predict Their Outcomes and Differentiate Between Axonal and Demyelinating Subtypes.

Peripheral NeuropathyChronic Inflammatory Demyelinating PolyradiculoneuropathyGuillain Barré Syndrome+2 more
Assiut University90 enrolled1 locationNCT06615622
Recruiting
Phase 1Phase 2

Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases

Myasthenia GravisNMO Spectrum DisorderChronic Inflammatory Demyelinating Polyradiculoneuropathy+1 more
Tianjin Medical University General Hospital27 enrolled1 locationNCT07022197
Recruiting

Biomarkers in Autoimmune Disease of Nervous System

Myasthenia GravisAutoimmune EncephalitisMultiple Sclerosis+8 more
Tongji Hospital50,000 enrolled1 locationNCT06502015
Recruiting
Early Phase 1

Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System

Myasthenia GravisAutoimmune EncephalitisMultiple Sclerosis+7 more
Tongji Hospital36 enrolled1 locationNCT04561557